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Objective: To clarify the role of common genetic variation in the Interleukin-1b (IL1B) and Interleukin-1R
antagonist (IL1RN) genes on risk of knee and hip osteoarthritis (OA) and severity of knee OA by means of
large-scale meta-analyses.
Methods: We searched PubMed for articles assessing the role of IL1B and IL1RN polymorphisms/haplo-
types on the risk of hip and/or knee OA. Novel data were included from eight unpublished studies. Meta-
analyses were performed using ﬁxed- and random-effects models with a total of 3595 hip OA and 5013
knee OA cases, and 6559 and 9132 controls respectively. The role of ILRN haplotypes on radiographic
severity of knee OA was tested in 1918 cases with KellgreneLawrence (K/L) 1 or 2 compared to 199 cases
with K/L 3 or 4.
Results: The meta-analysis of six published studies retrieved from the literature search and eight
unpublished studies showed no evidence of association between common genetic variation in the IL1B or
IL1RN genes and risk of hip OA or knee OA (P> 0.05 for rs16944, rs1143634, rs419598 and haplotype C-G-
C (rs1143634, rs16944 and rs419598) previously implicated in risk of hip OA). The C-T-A haplotype
formed by rs419598, rs315952 and rs9005, previously implicated in radiographic severity of knee OA,
was associated with reduced severity of knee OA (odds ratio (OR)¼ 0.71 95%CI 0.56e0.91; P¼ 0.006,Hanneke J.M. Kerkhof, Genetic Laboratory, Department of Internal Medicine, Room Ee2183, Erasmus Medical Center
e Netherlands. Tel: 31-10-70-44-292.
. Kerkhof).
ternational. Published by Elsevier Ltd. Open access under the Elsevier OA license.
H.J.M. Kerkhof et al. / Osteoarthritis and Cartilage 19 (2011) 265e271266I2¼ 74%), and achieved borderline statistical signiﬁcance in a random-effects model (OR¼ 0.61 95%CI
0.35e1.06 P¼ 0.08).
Conclusion: Common genetic variation in the Interleukin-1 region is not associated with prevalence of hip
or knee OA but our data suggest that IL1RN might have a role in severity of knee OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd.
Open access under the Elsevier OA license.Introduction
Osteoarthritis (OA) is a multifactorial disease of the musculo-
skeletal system primarily involving the joints of the knee, hip, hand
and spine. The prevalence of OA increases with age and is estimated
to affect 40% of people over the age of 70 years1. There is a large
body of evidence that synovial inﬂammation is implicated in many
of the signs and symptoms of OA, including joint swelling and
effusion2. This synovitis is cytokine-driven and there is convincing
evidence that chondrocytes contribute to cytokine production
leading to cartilage matrix degradation and in fact a number of
variants in genes encoding for cytokines, in particular Interleukin-1
(IL-1), IL-6 and IL-10 involved in inﬂammation, have been reported
to be associated with risk of OA as shown in a recent review3,4.
Chondrocytes are known to respond to IL-1 beta and alpha (IL1B,
IL1A) by decreasing synthesis of matrix components and increasing
synthesis of matrix metalloproteinases3. The IL-1 receptor antag-
onist (IL1RN gene) could antagonise the effects of both IL1A and
IL1B. In addition, it was recently shown that carriers of the IL1RN
C-T-A haplotype had signiﬁcantly lower synovial ﬂuid levels of Il-10
and trends towards lower levels of Il-6 and IL1B5. It is therefore
expected that carriers of this haplotype are able to antagonise the
effects of IL-1 and therefore reduce the risk of OA.
Several studies have investigated the role of polymorphisms in
the IL-1 gene on knee and hip OA, in particular IL1B Cþ 3954T
(rs1143634), IL1B A-511G (rs16944) and the IL1RN 86 bp intron two
variable number tandem repeat (VNTR) (tagged by rs419598), but
results are conﬂicting6e15. One haplotype, C-G-C (rs1143634,
rs16944 and rs419598), was associatedwith an increased risk of hip
OA in two studies (in total 144 cases and 1501 controls)10,14.
However, this could not be replicated by another study (370 cases,
544 controls)6. Recently, a small meta-analysis (n¼ 1238 hip, knee
and hand OA cases and 1260 controls) has been published on the
IL-1 region and OA, but remained inconclusive16. In that meta-
analysis, some studies (n¼ 4) with data available on allele
frequencies of single nucleotide polymorphisms (SNPs) rs16944,
rs419598 or rs1143634 (or SNPs/VNTR in linkage disequilibrium
(LD) with these three SNPs) and knee and/or hip OA data were not
included in the ﬁnal analysis.
In 2009, Attur and colleagues explored the role of IL1RN variants
on radiographic severity5. It was shown in two studies (n total¼ 130)
that carriers of the C-T-A haplotype (rs419598/rs315952/rs9005) had
a signiﬁcantly decreased risk for severe kneeOA (odds ratio (OR) 0.14,
95%CI 0.05e0.37, P< 0.0001 for the haplotype analysis). The CC/CT
genotype at rs419598, was also reported in the same study to be
signiﬁcantly associated with radiographic severity (OR 0.22 95%CI
0.10e0.49).
Our scope was to clarify the role of rs1143634, rs16944 and
rs419598 IL1B and IL1RN polymorphisms on risk of knee and hip OA.
To do so, we have carried out a largemeta-analysis of both published
data (n¼ 6) and unpublished new studies (n¼ 8), comprising a total
3595 hip OA cases and 6559 controls and 5013 knee OA cases and
9132 controls. Because one of these variants has also been implicated
in severity of knee OA, a meta-analysis on severity of knee OA with
rs419598 was also carried out in eight new studies plus the original
report. To detect association between severity of knee OA and the
C-T-A haplotype, three studies and the original report were meta-
analysed.Subjects and methods
Study subjects
Unpublished studies with novel data
A full detailed description of each study cohort on recruitment,
radiographic and clinical assessment is presented in the
Supplementary methods section. In this meta-analysis, ﬁve studies
are available with data on common genetic variation in the IL-1
region for hip OA and eigth studies for knee OA. The baseline char-
acteristics and sample size of these studies are shown in Table Ia. In
total seven cohort studies originating from three countries were
included. We included studies from the United Kingdom (UK): the
Chingford Study (CS)17,18, TwinsUK19 and the Hertfordshire Cohort
Study (HCS)20, the Netherlands: Rotterdam Study I and III (RSI,
RSIII)21 and theGenetics osteoARthritis and Progression Study (GARP
Study)22 and Estonia: Estonia Cohort Study (ECS)23. Also, one case-
control study fromNottingham (NCCS) (UK) is included24. All studies
were approved by the relevant Ethics Committee and
informed consent was obtained from all study participants
(see Supplementary methods section). In addition, severity of knee
OAwas studied in seven of these studies and in one additional study
(CS, GARP, HCS, NCCS, RSI, RSIII, TwinsUK and GOAL).
Published studies
We searched PubMed for relevant articles assessing the relation-
shipbetweengenetic variation in the IL-1 regionandknee andhipOA.
In Table Ib the baseline characteristics and sample size of six studies
identiﬁed by our search are given. Since not all studies published
allele and/or haplotype counts we contacted the authors if necessary
to obtainhaplotype and allele counts to performameta-analysiswith
aminimumamount of bias.Wewere not able to retrieve allele counts
for the controls of one Japanese Study7 and for the London samples
published by Smith et al. excluding participants from the CS15.
Therefore, these samples were not included in the meta-analysis. In
addition, in the study of Meulenbelt et al. a subset of the RSI was
used10. For this study we have now included the complete RSI and
therefore results of Meulenbelt et al. are not shown separately.
Meta-analysis
For the meta-analysis we were able to include 14 studies on knee
OA for one or more variants and eight studies on hip OAwith a total
number of up to 3595 hip OA cases and 6559 controls and 5013 knee
OA cases and 9132 controls. In addition, one study (n¼ 130 knee
radiographic osteoarthritis (ROA) cases from two cohorts) published
data on radiographic severity of knee OA and common genetic
variation in the IL-1 region5. We included this study in the meta-
analysis of severity of knee OA. One study with already published
data on the relationship between knee and hip OA and common
genetic variation in the IL-1 region, provided also unpublished data
on severity of knee and hip OA (GOAL Study)8 and was therefore also
included in the meta-analysis on severity of knee OA.
Laboratory methods
GARP study
The genotypes of rs1143634, rs16944 and rs419598 were
determined by mass spectrometry (homogeneous Mass ARRAY
Table Ia
Baseline characteristics of unpublished studies assessing the relationship between common genetic variation in the Il-1 region and risk of hip and knee OA
Study Chingford study Esto cohort GARP study Hertfordshire
cohort study
Nottingham case-
control study
Rotterdam study I Rotterdam
study III
TwinsUK Total
Study characteristics Type of study
Origin
Cohort
UK
Coho
Esto
Cohort
Netherlands
Cohort
UK
Case-control
UK
Cohort
Netherlands
Cohort
Netherlands
Cohort
UK
Controls Deﬁnition No ROA No R e No ROA No ROA & no
symptoms
No ROA No ROA No ROA 6836/4920
Number* 547/671 430 ey 772 750 2115/2777 1514 708/722
Age mean (range) 63.6 (54e76)z 46.5 e59) e 64.9 (59e71) 66.4 (43e93) 66.1 (55e89) 55.8 (46e89) 52.0 (32e70)
BMI mean (range) 24.8 (17e42)z 27.7 e45) e 26.6 (17e45) 26.6 (17e42) 25.7 (16e60) 27.5 (14e57) 24.3 (16e37)
% women 100% 70% e 51% 56% 54% 56% 100%
Hip OA cases Deﬁnition ROA e COA/ROA e THR ROA e ROA 1884
Number 95 e 81 e 1126 512 e 70
Age mean (range) 66.1 (55e76) e 63 (62e65) e 68.5 (40e90) 68.2 (55e93) e 56.6 (41e79)
BMI mean (range) 24.9 (19e37) e 26.5 (26e27) e 27.7 (15e50) 26.5 (18e43) e 25.3 (16e40)
% women 100% e 75% e 63% 59% e 100%
Knee OA cases Deﬁnition ROA ROA COA/ROA ROA ROAþ 80% TKR ROA ROA ROA 2882
Number 264 65 115 143 1174 866 151 104
Age mean (range) 65.9 (55e76) 51.0 e60) 61.6 (60e63) 65.2 (59e71) 69.3 (40e96) 70.3 (55e94) 58.0 (47e81) 58.9 (41e79)
BMI mean (range) 27.3 (19e45) 30.6 e47) 28.0 (27e29) 29.4 (21e48) 29.9 (16e51) 27.7 (18e50) 29.9 (19e48) 27.5 (21e52)
% women 100% 66% 82% 42% 56% 73% 57% 100%
ROA¼ radiographic osteoarthritis; COA¼ clinical osteoarthritis; THR¼ total replacement; TKR¼ total knee replacement.
* Knee OA controls and hip OA controls respectively if both phenotypes a resent in one study.
y Controls of the RSI are used as controls for the GARP Study.
z Average for hip and knee controls.
Table Ib
Baseline characteristics of published studies assessing the relationship betw common genetic variation in the Il-1 region and risk of hip and knee OA
Study Bristol Study Chinese Study Czech Study GOAL Oxford Study Turkish Study Total
Study characteristics Reference Smith et al.13,14 Ni et al.10 Ruzickova et al.11 Limer et al.7 Loughlin et al.5,8 Sezgin et al.12
Type of study Case-control Case-control Case-control Case-control Case-control Case-control
Origin UK China Czech Republic UK UK Turkey
Age mean (range) 62* 58 54.1y 66.5 (45e86) 73 (56e90) 61.3 (41e83)
BMI mean (range) e e e 29.3 (17e58) e 29.9 (21e44)
% women 52% 68% 68%z 49% 61% 75%
Controls Deﬁnition Unrelated healthy
blood donors
Healthy controlsx Healthy individuals No ROA & no
symptoms
Unaffected spouses No OA according to
ACR criteria
2296/1639
Number k 195 487 170 820 557 67
Hip OA cases Deﬁnition THR e e Croft score 3 THR e 1711
Number 29 e e 1299 383 e
Knee OA cases Deﬁnition COA/ROA COA/ROA COA/ROA COA/ROA TKR ACR criteria 2131
Number 141 453 50 1247 133 107
* Mean age in cases.
y Median age in cases.
z Percentage women in cases.
x Healthy controls from the Center at Physical Examination.
k Knee OA controls and hip OA controls respectively if both phenotypes ar esent in one study; ROA¼ radiographic osteoarthritis; COA¼ clinical osteoarthritis; THR¼ total hip replacement; TKR¼ total knee replacement.
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Genotypes were analysed by using Genotyper 3.0 software
(Sequenom Inc.). Control subjects of the RSI were used as controls
for the GARP study.
RSI and III
Genotypes were subtracted from the genome-wide association
(GWAS) dataset of the RSI and III. Genotyping of the samples with
the Illumina HumanHap550v3 Genotyping BeadChipwas carried out
at the Genetic Laboratory of the Department of Internal Medicine of
Erasmus Medical Center, Rotterdam, the Netherlands. The Bead-
studio GenCall algorithm was used for genotype calling and quality
control procedures were as described previously25,26. Missing
genotypes for RSI and III were imputed as described previously27.
Subsequently, genotypes of rs1143634, rs16944, rs419598, rs315952
and rs9005 were subtracted using PLINK software V1.0728. All ﬁve
polymorphisms were in HWE in controls in both studies (P> 0.05,
data not shown).
TwinsUK Study
Genotypes were subtracted from the GWAS dataset of the
TwinsUK study27 using the same methods as for RSI and RSIII. All
polymorphisms were in HWE in controls (P> 0.05, data not
shown).
Other studies
For the NCCS, HCS, CS and ECS study participants, genomic DNA
was extracted from peripheral blood leukocytes of affected indi-
viduals and controls using standard protocols. Genotyping was
carried out by Kbioscience Ltd, Hertfordshire UK. The IL-1 SNPs
were genotyped using the KASPar chemistry, which is a competi-
tive allele-speciﬁc PCR SNP genotyping system using FRET
quencher cassette oligos. Genotyping accuracy, as determined from
the genotype concordance between 52 duplicate samples was
99.35% for all three SNPs. All three polymorphisms were in
HardyeWeinberg equilibrium in controls (P> 0.05).
Haplotype estimation
In Supplementary Fig. 1 we show the LD plot for Il-1. LD is low
between the rs16944, rs1143634 and rs419598 (lowest D0 ¼ 0.38
and r2¼ 0.02). In addition, in Supplementary Table I we show D0
and r2 values between rs16944, rs1143634 and rs419598 for all
studies contributing novel data to this meta-analysis. For all new
studies as well as for GOAL we estimated haplotypes on a pop-
ulation level using the program Haploview v 4.129. In all studies,
seven common haplotypes were present for hip OA (rs1143634,
rs16944 and rs419598). For the remainder of published studies the
haplotype frequencies reported by authors were used and theTable II
Meta-analyses association results for common genetic variation in the IL-1 region and ri
SNP/Haplotype Phenotype N cases N controls Association results
OR 95%CI
rs1143634 Knee OA 4429 8549 1.03* 0.95e1.12
rs16944 4761 8770 1.02 0.96e1.08
rs419598 4900 9195 1.05* 0.97e1.14
rs1143634 Hip OA 3634 7918 0.97 0.90e1.04
rs16944 3605 7725 1.04* 0.95e1.14
rs419598 3619 7897 1.00 0.93e1.08
C-G-C haplotype 3654 8131 1.04* 0.93e1.17
All association results are ﬁxed-effects ORs unless indicated otherwise; OA¼ osteoarthri
C-G-C haplotype¼ rs1143634-rs16944-rs419598.
* Random-effects model.reader is referred to the original studies (see Table Ia and Ib and
Supplementary Table II).
Statistical analysis
Allele and genotype ORswere calculated by comparing the allele
and genotype frequencies between cases and controls. Three SNPs,
previously implicated in risk of hip and knee OA, rs16944,
rs1143634 and rs419598, were tested for association with knee and
hip OA. In addition, the haplotype C-G-C or 1-1-2 which was
reported as signiﬁcantly associated with hip OA in two previous
studies (rs1143634, rs16944 and rs419598), was tested for associ-
ation with hip OA10,14.
To be consistent with the previously published study by Attur
et al. we classiﬁed patients as severe knee OA case if the K/L score
of the knee was 3 or 4 and as mild to moderate knee OAwith a K/L
score of 1 or 25. The studies with data for this type of analysis are
CS, GARP, GOAL, HCS, NCCS, RSI, RSIII and TwinsUK, totalling 3297
individuals with K/L 1 or 2, and 2243 with K/L 3 or 4 (Table III).
These were combined to 130 individuals with K/L 1 or 2 from the
original US study and individuals with K/L 3 or 4. In addition, for
TwinsUK, RSI and RSIII were able to estimate the C-T-A haplotype
consisting of respectively rs419598, rs315952 and rs9005. A
meta-analysis was performed for both the C allele of rs419598
and for the C-T-A haplotype with severity of knee OA. We carried
out both ﬁxed-effects and random-effects meta-analyses as
follows:
Meta-analyses
We synthesized the effect estimates in each study using ﬁxed-
and random-effects models. In ﬁxed-effects calculations it is
assumed that the true effect of risk allele is the same value in each
study, whereas in random-effects calculations the risk allele effects
for the individual studies are assumed to vary around some overall
average effect. We assessed the presence of heterogeneity using the
Cochran’s Q-statistic30. The heterogeneity was quantiﬁed by using
the I231. In the absence of at least moderate inter-study heteroge-
neity within samples (I2< 25%) we conducted a ManteleHaenszel
meta-analysis of data from the samples to assess the overall
evidence of association32. For the random-effects models we used
the DerSimonianeLaird method which incorporates the heteroge-
neity between studies. The overall treatment effect is estimated by
a weighted average of the individual effects with weights inversely
proportional to the variance of the observed effects. The statistical
signiﬁcance of the DerSimonianeLaird OR was estimated using the
Z-statistic (the point estimate to its standard error). If evidence of
heterogeneity existed, deﬁned as either P< 0.10 for the Q-statistic
and/or I2> 25%, a random-effects model was applied for the meta-
analysis.sk of hip and knee OA
Heterogeneity statistics Statistical power
P-value I2 Q df P-value (Q) Minimal OR for 80%
power alpha¼ 0.05
0.43 21% 12.7 10 0.24 1.088
0.57 0% 6.4 10 0.78 1.078
0.24 32% 17.5 12 0.13 1.082
0.40 0% 3.7 6 0.72 1.096
0.35 36% 9.4 6 0.16 1.088
0.97 0% 5.7 6 0.46 1.093
0.52 44% 12.4 7 0.09 1.148
tis; df¼ degrees of freedom.
Table III
Genotype and haplotype frequencies for knee severity replication studies
study Nottingham Case-
Control study
HCS CS GOAL GARP Study RSI RSIII TwinsUK
K/L score 1e2
N 399 310 180 329 161 1283 490 145
rs419598 CC/CT 45.4% 44.8% 57.6% 50.5% 45.3% 46.1% 46.1% 53.1%
C-T-A haplotype N/A N/A N/A N/A N/A 24.9% 24.6% 27.9%
K/L score 3e4
N 981 45 164 796 58 103 40 56
rs419598 CC/CT 48.8% 66.7% 54.5% 50.1% 43.1% 45.6% 37.5% 48.2%
C-T-A haplotype N/A N/A N/A N/A N/A 21.3% 19.9% 25.6%
Results for the C-T-A haplotype refer to: rs419598-rs315952-rs9005 C-T-A haplotype; n¼ number of subjects.
N/A¼ not applicable.
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Statistical power was computed using Quanto 1.2.4 (University
of Southern California, USA, http://hydra.usc.edu/gxe).A
0.01 0.1 0.2 0.5 1 2 5
summary (random effects) 0.92 (0.71, 1.20)
NYUHJD 0.22 (0.10, 0.49)
Hertfordshire 2.46 (1.27, 4.76)
GARP 0.91 (0.50, 1.67)
RSIII 0.70 (0.36, 1.36)
RSI 0.98 (0.66, 1.47)
Nottingham 1.15 (0.91, 1.45)
TwinsUK 0.82 (0.44, 1.52)
GOAL 0.99 (0.76, 1.28)
Chingford 0.88 (0.55, 1.43)
OR (95%CI) rs419598 CC/CT genotype Results
For the statistical power for each meta-analysis, given the
frequency of the minor allele and the sample sizes available, it was
estimated that we had 80% power to ﬁnd associations with an
OR¼ 1.09e1.15 (dependingontheallele frequencyandonthenumber
of studies with data for each SNP) for hip OA and OR¼ 1.08e1.09 for
knee OAwith P< 0.05 (Table II).
The allele andhaplotype frequencies for cases and controls in each
study are presented in Supplementary Table IIa and b respectively for
unpublished and published studies. The summary results of the hip
and kneeOAmeta-analyses for rs1143634, rs16944 and rs419598and
haplotype C-G-C for hip OA are presented in Table II. No signiﬁcant
associationswere observed between rs16944, rs1143634 or rs419598
and hip or knee OA (P> 0.05). No association was seen between the
C-G-C haplotype and hip OA OR¼ 1.06 (95%CI 0.90e1.24 P¼ 0.52)
(Fig. 1).
The genotype and haplotype frequencies for severe knee OA cases
(K/L 3 and 4) and controls (K/L 1 or 2) in each study are presented in
Table III. No evidence of association between risk of severe knee and
the ILRN SNP rs419598 region was observed [Fig. 2(A)]. Speciﬁcally,
rs419598 had an OR of 1.06 (95%CI 0.93e1.22, P¼ 0.78) for severe
knee OA. Very strong heterogeneity (I2¼ 70%, Q-statistic P¼ 0.002)
was observed for this analysis. Excluding the initial signiﬁcant report
and data from the HCS (which shows a signiﬁcant association in the
opposite direction) no between study heterogeneity remainedepytolpahC-G-C895914sr-44961sr-4363411sr)IC%59(RO
2.0 5.0 1 2 5 01
)71.1,39.0(40.1yrammus
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Fig. 1. Study speciﬁc estimates and summary association (random-effects) between
risk of hip OA and rs1143634-rs16944-rs419598 “C-G-C” haplotype on risk of hip OA.(I2¼ 0%) and the effect of this genotype became OR¼ 1.00 (95%CI
0.87e1.15; P¼ 0.97) indicating no role for this genotype in severity of
knee OA.When a ﬁxed-effects meta-analysis were performed for the
haplotype reported to be associated with OA radiographic severity
[Fig. 2(B)] a trend was observed in the same direction in all three
replication studies and combined with the initial report from Attur
and co-workers16 a summary effect of OR¼ 0.71 (95%CI 0.56e0.91;
P¼ 0.006) was observed. Nevertheless, the extremely strong effect
reported by the ﬁrst study introduces signiﬁcant heterogeneity
(I2¼74%Q P¼ 0.008) and a random-effectsmeta-analysis resulted in
OR¼ 0.61 (95%CI 0.35e1.06 P¼ 0.08) [Fig. 2(B)].B OR rs419598- rs315952 -rs9005 C-T-A haplotype 
0.01 0.1 0.2 0.5 1 2
summary (random effects) 0.61 (0.35, 1.06)
NYUHJD 0.14 (0.05, 0.37)
RS III 0.76 (0.43, 1.34)
RS I 0.82 (0.58, 1.15)
TwinsUK 0.89 (0.54, 1.46)
Fig. 2. Study speciﬁc estimates and summary association (random-effects) between
severity of knee OA deﬁned as K/L 1 or 2 vs K/L 3 or 4 and (A) rs419598 CC/CT genotype,
(B) haplotype rs419598, rs315952 and rs9005 “C-T-A”.
H.J.M. Kerkhof et al. / Osteoarthritis and Cartilage 19 (2011) 265e271270Discussion
This meta-analysis on common genetic variation in the IL-1
region and risk of hip and knee OA is the largest to date, including
all available published studies (n¼ 6) and unpublished novel data
(n¼ 8), and shows no evidence for a consistent association with
knee or hip OA. In this study we had 80% power to detect
OR¼ 1.09e1.15 for hip OA and OR¼ 1.08e1.09 for knee OA with
a¼ 0.05. Therefore it is not likely that we have observed false-
negative associations with regards to risk. Nevertheless, we ﬁnd
that the IL1RN C-T-A haplotype may indeed have a role in severe
knee OA which is consistent with the well known IL1’s established
role as a regulator of cartilage degradation3,5. Since there is
a limited sample size of subjects of a non-Caucasian origin, we
cannot exclude that there might be evidence of association
between the SNPs studied and OA in subjects from a different
ethnic origin.
So far, the literature has been inconclusive on the role of IL-1
polymorphisms and/or haplotypes in risk of knee and hip OA,
probably due to low sample sizes of individual studies. An
attempt was made by Moxley and colleagues to perform a meta-
analysis, but the results remained inconclusive16. One of the
reasons for this could be that they did not include all published
studies on genetic variation in the Il-1 region. More importantly
the authors did not add unpublished novel data. This approach
resulted in not only low power to detect statistically signiﬁcant
associations, but could potentially also lead to publication bias.
There were not enough published studies examining the same
genetic variant in relation to OA to study presence of publication
bias.
In two previous publications the C-G-C haplotypewas associated
with an increased risk of hip OA, although this could not be repli-
cated by another larger study6. In this meta-analysis, which had 25
times more cases compared to the ﬁrst two publications, we could
not ﬁnd evidence of an association between this haplotype and hip
OA. Thereforewe conclude that the previous two observationswere
false positive10,14.We also have to note that there is low LD between
the three SNPs (two SNPs in the IL1B gene and one SNP in the IL1RN
gene) in all Caucasian populations studied and therefore an analysis
of haplotypes in Caucasian populations is not appropriate, which is
true for this study and all previous publications.
Recently, a small study (n¼ 130 cases) showed that genetic
variation in the IL-1 region was associated with severity of knee
OA5. We ﬁnd very strong heterogeneity in the association between
the ILRN variant rs419598 and knee OA severity and overall there is
no signiﬁcant effect. Yet, when we tested the C-T-A haplotype
associated with severe knee OA we found that in all studies it had
a lower frequency among severe OA cases than non-severe cases
suggesting that it might be truly involved in this phenotype. We
observed a borderline signiﬁcant effect in the random-effects
model for the C-T-A haplotype and severe knee OA, but power was
limited for this analysis and therefore a larger sample size or
functional studies are needed to conﬁrm the role of ILRN in severe
knee OA.
In conclusion, common genetic variation in the IL-1 region is not
associated with prevalence of hip or knee OA but our data suggest
that IL1RN might have a role in severity of knee OA.Author’s contributions
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